MASTERINVEST Kapitalanlage GmbH Acquires 2,845 Shares of Johnson & Johnson $JNJ

MASTERINVEST Kapitalanlage GmbH increased its stake in Johnson & Johnson (NYSE:JNJ) by 18.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,242 shares of the company’s stock after acquiring an additional 2,845 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in Johnson & Johnson were worth $3,382,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $28,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the second quarter worth $27,000. Semmax Financial Advisors Inc. boosted its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. GFG Capital LLC bought a new position in Johnson & Johnson during the second quarter valued at $35,000. Finally, Signature Resources Capital Management LLC raised its stake in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $209.79 on Tuesday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $203.34 and a two-hundred day simple moving average of $185.38. The stock has a market capitalization of $505.45 billion, a price-to-earnings ratio of 20.25, a P/E/G ratio of 2.10 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on JNJ shares. Barclays lifted their price target on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 30th. Guggenheim boosted their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Argus set a $210.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a report on Wednesday, December 17th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.